Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Lilian Gien MD
Closed to Accrual
To assess the objective tumor response (proportion of objective response by RECIST 1.1 criteria) of the combination of MK-3475 (pembrolizumab) and epacadostat in patients with recurrent or persistent clear cell carcinoma of the ovary
Women with recurrent or persistent clear cell carcinoma of the ovary.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.